A. H.

[A. H. @AH51497]

@seedy19tron Would love to join

[A. H. @AH51497]

@CloisterRes Slide making better than Claude?

[A. H. @AH51497]

@WallStSai Didn't we already know this?
https://t.co/guzr1z7tRa

[A. H. @AH51497]

@BiotechObserver Arguably will have more liver benefit in MASH compared to Sema

[A. H. @AH51497]

@ProfGigaMind @CloisterRes https://t.co/JAqhie18Co

[A. H. @AH51497]

@avidresearch What's the read through? It's a different MOA

[A. H. @AH51497]

@Biotenic Prasad’s employment at FDA

[A. H. @AH51497]

@MelvinRiskMgmt @PreciseSVJ Forgive my ignorance but how do you know most of ARR for epi is from institutions?

[A. H. @AH51497]

@biofeed After neffy’s CRL, ARS ran studies to show this wasn’t an issue, but it seems there’s a negative sentiment

[A. H. @AH51497]

@MelvinRiskMgmt @Michaelrose102 @houndcl @NicholasChoupak @a_a_free Because of access?

[A. H. @AH51497]

@biofeed Wonder why Narcan and Valtoco don't have these hesitations tho

[A. H. @AH51497]

@biofeed Why not?

[A. H. @AH51497]

@3rdFloorCapital

[A. H. @AH51497]

@Biohazard3737 $DRUG

[A. H. @AH51497]

@West0_Cap Why?

[A. H. @AH51497]

@BalaBioResearch @TCellEngager SAVA longs weren’t rational but stock still dropped hard after the trial failed

[A. H. @AH51497]

@jeremyj0916 $AVXL next

[A. H. @AH51497]

@aditharun_ the analysts/ banks that publish research want companies to use them for financings or M&A. Optimistic valuations helps keep management happy and more likely to use the bank

[A. H. @AH51497]

@A_May_MD @Sanctuary_Bio @Getoutofmyway1 My thought was that while CM drives costs like hospitalizations and acute cardiac interventions, the main FA cost driver comes from neuro disability and long term care needs. But the former is still pretty costly, to your point

[A. H. @AH51497]

@A_May_MD @Sanctuary_Bio @Getoutofmyway1 But is LXEO’s cardiac frataxin really any better? Payers care about costs of care/ disability. CM drives mortality, not so much disability (driven by neuro)